Peptide-Based Lyme Disease Diagnostic Assay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current serologic assays for Lyme disease diagnosis suffer from low sensitivity and specificity, particularly in early stages, necessitating a more effective method for early detection.
Innovation Solution
Identification of specific peptides that recognize antibodies against pathogenic Borrelia burgdorferi, allowing for a sensitive and specific diagnostic approach using peptide-based assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current serologic assays (ELISA, IFA, western blot) are used for Lyme disease diagnosis, then the diagnosis can be performed, but the sensitivity and specificity are low especially in early disease stages
Solution Approach 1:
The patent segments the diagnostic approach by using multiple distinct peptides (at least 2 different peptides) instead of a single antigen. Each peptide targets specific antibody responses, allowing the assay to detect different aspects of the immune response to Borrelia burgdorferi, thereby improving both sensitivity and specificity in early disease stages
Solution Approach 2:
The patent changes the diagnostic parameters by using synthetic peptides with specific amino acid sequences derived from Borrelia burgdorferi proteins. These peptides have optimized properties for detection, including specific epitopes that elicit strong antibody responses, improving the measurement precision and reliability of the diagnostic assay
2Measurement precision
If a two-tier assay approach (first tier ELISA/IFA followed by second tier western blot) is used, then specificity is improved, but the diagnostic process becomes more complex and time-consuming
Solution Approach 1:
The patent merges the functions of first-tier screening and second-tier confirmation into a single assay format. By using multiple peptides in one ELISA or lateral flow assay, the method simultaneously achieves high sensitivity for screening and high specificity for confirmation, eliminating the need for sequential two-tier testing
Solution Approach 2:
The patent creates a multi-functional diagnostic assay that can serve both as a sensitive screening tool and a specific confirmatory test. The use of multiple peptides with different specificities allows the same assay to detect early infections (high sensitivity) and confirm diagnoses with high accuracy (high specificity), making the assay universally applicable for all diagnostic stages
3Measurement precision
If a two-tier assay approach is used, then diagnostic specificity is improved, but the time required for diagnosis increases by a week or more
Solution Approach 1:
The patent performs preliminary action by incorporating multiple peptide targets into a single assay format from the outset. This allows the diagnostic test to simultaneously capture and differentiate various antibody responses in one measurement, eliminating the sequential waiting period between first-tier and second-tier assays and reducing total diagnosis time to a single day
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide-based diagnostic method enhances the sensitivity and specificity of Lyme disease detection, enabling early and accurate diagnosis, reducing the need for multiple assays and improving patient outcomes.
Implementation Method 1
specific peptides that recognize antibodies against pathogenic Borrelia burgdorferi
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1 - SEQ ID NO:28 or SEQ ID NO:41-SEQ ID NO:47, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Compositions of the invention may comprise multiple peptides, from multiple proteins. Diagnostic kits comprising the peptides are described, as are diagnostic assays using the peptides.